RealPennies.com: Turning Pennies into dollars: (OTCBB:PKTX) ProtoKinetix, Inc

For more info: http://www.realpennies.com/otc/pktx ProtoKinetix' AAGP is Critical for Stem Cell Therapy (OTCBB:PKTX) ProtoKinetix, Inc.

ProtoKinetix' AAGP is Critical for Stem Cell Therapy

VANCOUVER-Protokinetix' results over the last 2-years have clearly shown the vital role that AAGP- can play in this exciting disease treatment arena. Support for stem cell research has never been stronger and continues to grow. This growth will accelerate as successful results are announced.

One of the most important ingredients for the success of this therapy is the recovery of the maximum number of viable stem cells after storage. These extremely delicate cells typically have a very low yield after cryopreservation. AAGP- testing that has been conducted on stem cell preservation at all temperatures has shown an impressive increase in survivability and viability.

In summary, over the past 24-months, AAGP- has demonstrated a remarkable increase in viable cell recovery at temperatures ranging from -196-C all the way to 37-C. These results have been consistent regardless of the source of the stem cells. As an example, AAGP- has been independently tested as a protective agent in the cryopreservation and subsequent thawing of umbilical cord blood in low concentrations of AAGP-. The resultant analysis revealed a more than double average increase over the control group in the yield, following thawing.

About ProtoKinetix

ProtoKinetix Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP- products. For more detailed information, visit our website at: www.protokinetix.com The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company?s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO Contact: ProtoKinetix Inc. Investor Contact Blair Henderson, 604-687-9887 Source: PROTOKINETIX INC.

Profile for ProtoKinetix, Inc.

ProtoKinetix, Incorporated, a biotechnology company, engages in the research, development, and testing of a family of synthetic anti-aging glycopeptides for enhancing the health and extending the life of biologically sensitive cells. The commercial applications of AAGPs include harvesting, storage, and transplantation of cells, tissues, and organs; and treatments for conditions and disease caused by stress factors, including UV radiation, starvation, oxidation, temperature, and inflammation. The company was founded in 1999 and is based in Vancouver, Canada. Detailed PKTX Company Description...

LAST $0.11 USD Find out more about PKTX

Realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

CONTACT: RealPennies.com
Tel: +1 212 662 2147
e-mail: info@realpennies.com
WWW: http://www.realpennies.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (PKTX) PKTX. (PKTX) has Short Term PowerRatings at TradingMarkets. Details on (PKTX) Short Term PowerRatings is available at This Link.